volume 3, issue 2, P103-118 2010
DOI: 10.15283/ijsc.2010.3.2.103
View full text

Abstract: Background and Objectives: The field of Umbilical cord blood (UCB) hematopoietic stem cell transplantation has had an amazing run since 1988. UCB is being increasing used in related and unrelated transplant settings. A major hurdle, however, in the use of UCB is its low cell dose, which is largely responsible for an elevated risk of graft failure and significantly delayed neutrophils and platelet engraftment. Strategies to increase CD34 + HSC/HPC dose are under development as a direct correlation has been sho…

Expand abstract